– Kokolus KM, Zhang Y, Sivik JM, Schmeck C, Zhu J, Repasky EA, Joseph J. Drabick, et al. Beta blocker use correlates with better overall survival in metastatic melanoma patients and improves the efficacy of immunotherapies in mice. OncoImmunology, 2017; e1405205 DOI: 10.1080/2162402X.2017.1405205 /2162402X.2017.1405205
– Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med 2018;378:158-168.
– Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, et al. A Serum Protein Signature Associated with Outcome after Anti–PD-1 Therapy in Metastatic Melanoma. Cancer Immunology Research 2018; DOI: 10.1158/2326-6066.CIR-17-0412.
En la sección: Actualidades, Artículos de revisión, Inmunidad tumoral, Inmunoterapia. Publicado en: . 
